Railo M, Nordling S, Krogerus L, Sioris T, von Smitten K
Fourth Department of Surgery, Helsinki University Central Hospital, Finland.
Diagn Cytopathol. 1996 Sep;15(3):205-10. doi: 10.1002/(SICI)1097-0339(199609)15:3<205::AID-DC6>3.0.CO;2-F.
The applicability and reliability of estimates of proliferative activity in breast carcinomas using fine-needle aspiration (FNA) and needle-core biopsies (NC) was evaluated in 98 breast carcinoma patients. The Ki-67, Estrogen receptor (ER), and progesteron receptor (PR) immunolabelling of FNA and NC was compared with that of the surgical specimen. A statistically significant consistency between labelling was found in the Ki-67-NC (kappa = 0.474), ER-FNA (kappa = 0.318), ER-NC (kappa = 0.518), and PR-FNA (kappa = 0.404) groups. The consistency in the Ki-67-FNA group was less significant (kappa = 0.182), and there was no consistency in the PR-NC group (kappa = 0.062). There was a positive correlation of Ki-67 labelling in FNA and NC biopsies (Spearman rank, rho = 0.4; P = 0.0007), and also in ER labeling (Spearman rank rho = 0.6; P = 0.0001). These results indicate that NC and FNA can be used for preoperative assessment of proliferative activity and hormonal status in breast carcinoma.
对98例乳腺癌患者评估了使用细针穿刺（FNA）和针芯活检（NC）来估计乳腺癌增殖活性的适用性和可靠性。将FNA和NC的Ki-67、雌激素受体（ER）和孕激素受体（PR）免疫标记与手术标本的进行比较。在Ki-67-NC组（kappa = 0.474）、ER-FNA组（kappa = 0.318）、ER-NC组（kappa = 0.518）和PR-FNA组（kappa = 0.404）中发现标记之间存在统计学上显著的一致性。Ki-67-FNA组的一致性不太显著（kappa = 0.182），PR-NC组中没有一致性（kappa = 0.062）。FNA和NC活检中Ki-67标记存在正相关（Spearman秩相关，rho = 0.4；P = 0.0007），ER标记也存在正相关（Spearman秩相关rho = 0.6；P = 0.0001）。这些结果表明，NC和FNA可用于乳腺癌增殖活性和激素状态的术前评估。
